Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services (DHHS), Washington, D.C. (Ali); Real World Analytics and Alliances, Janssen Pharmaceutical Companies of Johnson & Johnson, Titusville, New Jersey (Tehrani); Health, Retirement, and Long-Term Analysis Division, Congressional Budget Office (CBO), Washington, D.C. (Mutter); IBM Watson Health, Cambridge, Massachusetts (Henke, O'Brien); U.S. Acute Care Solutions, Canton, Ohio (Pines); MedStar Washington Hospital Center, Washington, D.C. (Mazer-Amirshahi).
Psychiatr Serv. 2019 Aug 1;70(8):681-688. doi: 10.1176/appi.ps.201800555. Epub 2019 May 6.
Opioid analgesics can be safe and effective when used properly. Reducing prescriptions that increase adverse outcomes is a focus for addressing the opioid crisis. In this study, the rate of potentially problematic opioid prescriptions was examined over 11 years in a large sample of U.S. patients.
Claims from the IBM MarketScan commercial database (about 45 million) and multistate Medicaid database (about 7 million) from 2005 to 2015 were used to calculate rates of the following potentially problematic prescription practices: prescriptions for high-dose opioids for 90 days or more, prescriptions from multiple providers, prescriptions of long-acting or extended-release opioids for acute pain, overlap between prescriptions for opioids, and overlap between prescriptions for opioids and benzodiazepines.
Among patients with an opioid prescription, about 8% of those with private insurance and about 14% of those with Medicaid coverage had at least two incidents of potentially problematic prescriptions per year. Over the study period, rates increased for some practices (opioid-benzodiazepine overlap) and decreased for others (prescriptions from multiple providers). Receipt of potentially problematic prescriptions was higher among older patients, female patients with private insurance, and whites and male patients covered by Medicaid.
A significant percentage of patients who are prescribed opioids experience problematic prescription practices. Targeted policy and clinical interventions that reduce potentially problematic prescription could be a focus for addressing the U.S. opioid crisis.
阿片类镇痛药如果使用得当,可以安全有效。减少增加不良后果的处方是解决阿片类药物危机的重点。在这项研究中,在一个很大的美国患者样本中,研究了在 11 年内潜在有问题的阿片类药物处方的比率。
使用 IBM MarketScan 商业数据库(约 4500 万)和多州医疗补助数据库(约 700 万)中的索赔数据,计算以下潜在有问题的处方做法的发生率:90 天或更长时间的高剂量阿片类药物处方、来自多个提供者的处方、急性疼痛的长效或缓释阿片类药物处方、阿片类药物处方重叠以及阿片类药物和苯二氮䓬类药物处方重叠。
在有阿片类药物处方的患者中,约 8%的私人保险患者和约 14%的医疗补助覆盖患者每年至少有两次潜在有问题的处方。在研究期间,一些做法的发生率(阿片类药物-苯二氮䓬类药物重叠)增加,而其他做法(来自多个提供者的处方)减少。在接受潜在有问题的处方的患者中,年龄较大的患者、有私人保险的女性患者以及白人患者和医疗补助覆盖的男性患者的比例较高。
很大一部分接受阿片类药物处方的患者存在处方问题。减少潜在有问题的处方的有针对性的政策和临床干预措施可能是解决美国阿片类药物危机的重点。